Related Experiment Video
Updated: May 15, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Diffuse intrinsic pontine glioma: poised for progress
1Pediatric Neuro-Oncology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda, MD, USA.
Abstract:
Diffuse intrinsic pontine gliomas (DIPGs) are amongst the most challenging tumors to treat. Surgery is not an option, the effects of radiation therapy are temporary, and no chemotherapeutic agent has demonstrated significant efficacy. Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, yet without success. The diagnosis of DIPG is based on radiographic findings in the setting of a typical clinical presentation, and tissue is not routinely obtained as the standard of care. The paradigm for treating children with these tumors has been based on that for supratentorial high-grade gliomas in adults as the biology of these lesions were presumed to be similar. However, recent pivotal studies demonstrate that DIPGs appear to be their own entity. Simply identifying this fact releases a number of constraints and opens opportunities for biologic investigation of these lesions, setting the stage to move forward in identifying DIPG-specific treatments. This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies.
Insights
Diffuse intrinsic pontine gliomas (DIPG) are difficult pediatric brain tumors. Recent studies reveal DIPGs are a distinct entity, paving the way for targeted treatments.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Biology
Background:
- Diffuse intrinsic pontine gliomas (DIPG) are aggressive pediatric brain tumors.
- Current treatments including surgery, radiation, and chemotherapy have shown limited efficacy.
- DIPG diagnosis relies on imaging, with tissue biopsy not standard practice.
Purpose of the Study:
- To review the current understanding of DIPG biology and treatment challenges.
- To highlight recent findings that establish DIPGs as a unique tumor entity.
- To explore future directions for DIPG-specific therapeutic development.
Main Methods:
- Literature review of current DIPG research.
- Analysis of recent pivotal studies on DIPG biology.
- Synthesis of information on treatment obstacles and therapeutic opportunities.
Main Results:
- DIPGs have historically been treated based on adult high-grade glioma paradigms.
- Emerging evidence strongly suggests DIPGs are a distinct biological entity.
- This distinct classification opens new avenues for targeted research and treatment.
Conclusions:
- Recognizing DIPGs as a unique entity is crucial for advancing treatment strategies.
- Further biological investigation is essential for developing effective, DIPG-specific therapies.
- Overcoming treatment challenges requires a shift from generalized glioma approaches to DIPG-focused research.
